Intellia Therapeutics, Inc. Cash Flow Statement
NTLA / Health Care|12 years of annual SEC 10-K data (FY2014-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 12 fiscal years. All figures from audited SEC 10-K filings.
Intellia Therapeutics, Inc. used $395M in operating cash flow and negative free cash flow of $396M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$412.7M | -$519.0M | -$481.2M | -$474.2M | -$267.9M | -$134.2M | -$474.2M | -$85.3M | -$67.5M | -$31.6M | -$12.4M | -$9.5M |
| Depreciation & Amortization | $9.8M | $10.3M | $9.0M | $7.6M | $6.9M | $6.3M | $5.6M | $4.5M | $3.0M | $1.1M | $328.0K | $3.0K |
| Operating Cash Flow | -$394.7M | -$348.9M | -$394.1M | -$333.3M | -$225.0M | -$49.9M | -$103.2M | -$61.3M | -$65.3M | $36.1M | -$1.8M | -$2.3M |
| Capital Expenditures | $1.1M | $5.8M | $14.0M | $13.6M | $12.8M | $3.6M | $6.8M | $6.4M | $10.1M | $6.2M | $2.6M | $275.0K |
| Free Cash Flow | -$395.9M | -$354.7M | -$408.1M | -$346.8M | -$237.8M | -$53.5M | -$110.0M | -$67.6M | -$75.4M | $29.9M | -$4.3M | -$2.6M |
| FCF Margin | -585.0% | -612.8% | -1124.9% | -665.5% | -719.4% | -92.3% | -255.3% | -222.2% | - | - | - | - |